Quadrivalent Versus Trivalent Influenza Vaccine: Is It Good Value for Money?

M Barbieri, F Patarnello, S Boccalini, R Silvestri, J Lapinet, R Tosatto, F Kheiraoui, Chiara De Waure, P Bonanni, Walter Ricciardi

Risultato della ricerca: Contributo in rivistaContributo a convegno


Objective: To assess the cost-effectiveness of quadrivalent influenza vaccine (QIV) compared to trivalent vaccine (TIV) in the Italian population aged 65 years or more or at high-risk for influenza. Methods: A static and multi-cohort Markov model was modified to simulate the disease process of influenza (type A and B) over a lifetime horizon using annual cycles. Several cohorts based on the Italian population (nine different age-groups and two level of risks: high and low) entered the model and could be vaccinated with QIV, TIV or unvaccinated. Vaccine coverage rate, epidemiological and demographic estimates were taken from local statistics, surveillance data and Italian published studies, while circulation of type A versus B virus and type of lineage was taken from Euroflu estimates (from 2003-2004 to 2012-2013). Vaccine efficacy against influenza A and B were taken from 2 meta-analyses of clinical trials. Costs and resource use were based on local tariffs and published estimates (price year 2013). Quality of life scores were obtained from a Spanish study, using the EQ-5D questionnaire. The perspective of the National Health Service (NHS) was used and a 3% discount rate was applied to costs and benefits, according to Italian guidelines. To deal with the issue of uncertainty both deterministic and probabilistic sensitivity analyses were conducted. Results: In the basecase, the incremental cost per QALY and per LY saved for QIV versus TIV were €4.386 and €3.790, respectively. The most sensitive parameters were vaccine efficacy and probability of circulation of virus A versus B, but the ICER always remained lower than €10,000 per QALY. The probabilistic analysis showed that at a threshold of €50,000 per QALY, there was a 99% probability for QIV to be cost-effective. Conclusions: This study suggests that the introduction of QIV at €5.00 is likely to be a cost-effective strategy from the perspective of the Italian NHS.
Lingua originaleEnglish
pagine (da-a)A357-A357
RivistaValue in Health
Stato di pubblicazionePubblicato - 2013
EventoISPOR 16th Annual European Congress - Dublino
Durata: 2 nov 20136 nov 2013


  • Flu vaccine
  • HTA


Entra nei temi di ricerca di 'Quadrivalent Versus Trivalent Influenza Vaccine: Is It Good Value for Money?'. Insieme formano una fingerprint unica.

Cita questo